| The Australian rise of esomeprazole-was expenditure on samples a contributor? | |
| | |
MedLine Citation:
|
PMID: 19111014 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Administrative data from the Australian Pharmaceutical Benefits Scheme (PBS) showed rapid growth of esomeprazole dispensing when it was launched. Australia has universal prescription medicine coverage (the PBS), which included esomeprazole from August 2002. Free samples of new medicines are commonly provided to doctors. OBJECTIVES: To determine if a relationship exists between marketing expenditure on samples and the dispensing rate for esomeprazole in Australia between June 2002 and September 2006. METHODS: Quarterly sample expenditures at product/brand level for proton pump inhibitors (PPIs) for Australian general practitioners were obtained for July 2002 to September 2006. Corresponding PBS dispensing data were obtained for all PPIs and converted to defined daily dose (DDD)/1000 population/day. Spending on samples was calculated as dollars per dispensed prescription and plotted against time on the Australian market. RESULTS: Total PPI usage increased from 34.2 to 50.8 DDD/1000 population/day over the study period. Expenditure on samples per dispensed prescription was higher when a PPI was new on the market and diminished over 5-6 years to a relatively constant level. The rapid decline in this ratio was demonstrated by a case study following esomeprazole from launch in Australia for almost 5 years clearly demonstrating the initial investment to drive sales. CONCLUSION: A relationship appears to exist between expenditure on esomeprazole samples and its usage in Australia. A high initial investment was followed by a rapid reduction in cost per prescription dispensed, predominantly due to growth in market share. This trend was consistent with other PPIs. |
| | |
Authors:
|
Gregory J Kyle; Lisa M Nissen; Susan E Tett |
Related Documents
:
|
10153794 - The hmo-pbm relationship: getting along in today's market. 15126774 - Comparison of guide wires in urology. which, when and why? 10123314 - A practical guide for adapting to the 1992 cpt4 coding structure. 11010184 - Controlled-risk foreign investment strategy can boost yields. 21139144 - European guideline for the management of hepatitis b and c virus infections, 2010. 21866504 - A framework for evaluating evidence in evidence-based design. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Pharmacoepidemiology and drug safety Volume: 18 ISSN: 1099-1557 ISO Abbreviation: Pharmacoepidemiol Drug Saf Publication Date: 2009 Jan |
Date Detail:
|
Created Date: 2009-01-05 Completed Date: 2009-02-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9208369 Medline TA: Pharmacoepidemiol Drug Saf Country: England |
Other Details:
|
Languages: eng Pagination: 62-8 Citation Subset: IM |
Affiliation:
|
School of Pharmacy, The University of Queensland, Brisbane, Queensland 4072, Australia. g.kyle1@uq.edu.au |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anti-Ulcer Agents
/
economics,
therapeutic use* Australia Drug Costs / trends Drug Industry / economics, methods Humans Insurance Coverage / economics Insurance, Pharmaceutical Services / economics Marketing / economics*, methods Omeprazole / economics, therapeutic use* Physician's Practice Patterns / economics*, trends Proton Pump Inhibitors / economics, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Ulcer Agents; 0/Proton Pump Inhibitors; 73590-58-6/Omeprazole |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Medication adherence, first episode duration, overall duration and time without therapy: the example...
Next Document: Potentially inappropriate medication for emergency department visits by elderly patients in Taiwan.